Medpace Holdings PE Ratio 2014-2024 | MEDP
Current and historical p/e ratio for Medpace Holdings (MEDP) from 2014 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Medpace Holdings PE ratio as of December 20, 2024 is 29.35.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Medpace Holdings PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-12-20 | 337.28 | 29.53 | |
| 2024-09-30 | 333.80 | $11.42 | 29.23 |
| 2024-06-30 | 411.85 | $10.63 | 38.74 |
| 2024-03-31 | 404.15 | $9.81 | 41.20 |
| 2023-12-31 | 306.53 | $8.88 | 34.52 |
| 2023-09-30 | 242.13 | $8.54 | 28.35 |
| 2023-06-30 | 240.17 | $8.37 | 28.69 |
| 2023-03-31 | 188.05 | $7.90 | 23.80 |
| 2022-12-31 | 212.41 | $7.32 | 29.02 |
| 2022-09-30 | 157.17 | $6.52 | 24.11 |
| 2022-06-30 | 149.67 | $5.76 | 25.98 |
| 2022-03-31 | 163.59 | $5.36 | 30.52 |
| 2021-12-31 | 217.64 | $4.81 | 45.25 |
| 2021-09-30 | 189.28 | $4.84 | 39.11 |
| 2021-06-30 | 176.63 | $4.64 | 38.07 |
| 2021-03-31 | 164.05 | $4.22 | 38.87 |
| 2020-12-31 | 139.20 | $3.84 | 36.25 |
| 2020-09-30 | 111.75 | $3.27 | 34.17 |
| 2020-06-30 | 93.02 | $2.81 | 33.10 |
| 2020-03-31 | 73.38 | $2.90 | 25.30 |
| 2019-12-31 | 84.06 | $2.65 | 31.72 |
| 2019-09-30 | 84.04 | $2.48 | 33.89 |
| 2019-06-30 | 65.42 | $2.37 | 27.60 |
| 2019-03-31 | 58.97 | $2.09 | 28.22 |
| 2018-12-31 | 52.93 | $2.03 | 26.07 |
| 2018-09-30 | 59.91 | $1.72 | 34.83 |
| 2018-06-30 | 43.00 | $1.45 | 29.66 |
| 2018-03-31 | 34.91 | $1.23 | 28.38 |
| 2017-12-31 | 36.26 | $0.98 | 37.00 |
| 2017-09-30 | 31.90 | $0.68 | 46.91 |
| 2017-06-30 | 29.00 | $0.56 | 51.79 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.417B | $1.886B |
| Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization which provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $84.995B | 10.55 |
| Cencora (COR) | United States | $43.734B | 16.44 |
| DiDi Global (DIDIY) | China | $22.941B | 0.00 |
| Natera (NTRA) | United States | $20.871B | 0.00 |
| ICON (ICLR) | Ireland | $16.879B | 15.03 |
| Viatris (VTRS) | United States | $14.478B | 4.46 |
| Avantor (AVTR) | United States | $14.307B | 21.45 |
| Revvity (RVTY) | United States | $13.453B | 23.37 |
| BioMerieux (BMXMF) | France | $12.659B | 0.00 |
| CochLear (CHEOY) | Australia | $11.807B | 0.00 |
| Solventum (SOLV) | United States | $11.540B | 0.00 |
| Doximity (DOCS) | United States | $10.302B | 60.64 |
| Charles River Laboratories (CRL) | United States | $9.314B | 18.00 |
| HealthEquity (HQY) | United States | $8.212B | 41.20 |
| Sonic Healthcare (SKHHY) | Australia | $8.208B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.322B | 29.43 |
| Amplifon S.p.A (AMFPF) | Italy | $5.864B | 29.89 |
| Sotera Health (SHC) | United States | $3.759B | 20.11 |
| Organon (OGN) | United States | $3.719B | 3.75 |
| BrightSpring Health Services (BTSG) | United States | $2.967B | 63.11 |
| Surgery Partners (SGRY) | United States | $2.493B | 28.42 |
| Concentras Parent (CON) | United States | $2.491B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.291B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.069B | 0.00 |
| Premier (PINC) | United States | $2.067B | 10.76 |
| PACS (PACS) | United States | $1.992B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $1.969B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.730B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.711B | 44.90 |
| Teladoc Health (TDOC) | United States | $1.544B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.224B | 11.98 |
| Progyny (PGNY) | United States | $1.208B | 24.47 |
| Embecta (EMBC) | United States | $1.161B | 8.12 |
| CareDx (CDNA) | United States | $1.102B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.090B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.874B | 5.91 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| Agilon Health (AGL) | United States | $0.775B | 0.00 |
| SBC Medicals (SBC) | United States | $0.649B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.492B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.478B | 0.00 |
| DocGo (DCGO) | United States | $0.444B | 16.73 |
| Sonida Senior Living (SNDA) | United States | $0.441B | 0.00 |
| Enhabit (EHAB) | United States | $0.387B | 33.48 |
| Sera Prognostics (SERA) | United States | $0.275B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.268B | 0.00 |
| LifeMD (LFMD) | United States | $0.212B | 0.00 |
| Biodesix (BDSX) | United States | $0.198B | 0.00 |
| Beauty Health (SKIN) | United States | $0.176B | 0.00 |
| Nutex Health (NUTX) | United States | $0.160B | 0.00 |
| ModivCare (MODV) | United States | $0.156B | 8.44 |
| MultiPlan (MPLN) | United States | $0.108B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.099B | 0.00 |
| So-Young (SY) | China | $0.093B | 15.69 |
| IceCure Medical (ICCM) | Israel | $0.052B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.050B | 0.00 |
| OncoCyte (OCX) | United States | $0.037B | 0.00 |
| NeueHealth (NEUE) | United States | $0.033B | 0.87 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.023B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.023B | 0.00 |
| Oncology Institute (TOI) | United States | $0.016B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| KindlyMD (KDLY) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |